The purpose of this study is to assess the safety and feasibility of an oral probiotic supplement (PS) intervention in individuals with dementia or mild-cognitive impairment (MCI) due to Alzheimer's disease or at risk of dementia due to Alzheimer's disease (AD). 40 participants will be enrolled and can expect to be on study for up to 1 year.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety: Proportion of participants with an adverse event (AE) occurring during any point of the study
Timeframe: up to 36 weeks
Safety: Proportion of participants with a severe adverse event (SAE) occurring during any point of the study
Timeframe: up to 36 weeks
Feasibility: Number of weeks or months needed to meet study group numbers
Timeframe: up to 36 weeks
Feasibility: Proportion of individuals expressing interest in study who are Eligible
Timeframe: baseline
Feasibility: Proportion of Participants Who Complete 80 percent of Oral PS
Timeframe: week 24
Feasibility: Proportion of Participants Who Complete Intervention
Timeframe: up to 36 weeks